ProQR Signs Exclusive Worldwide License Agreement with Ionis for IONIS-RHO-2.5 Candidate (now QR-1123)
Shots:
- Ionis Pharmaceuticals will receive an upfront payment in ordinary shares $2.5M- $22.23/share representing 20% premium plus milestones payments and 20% royalties on net sales of QR-1123. ProQR to get WW license rights for Ionis’ IONIS-RHO-2.5 Candidate
- In 2019- ProQR plans onset of P-I/II trial for QR-1123 in autosomal dominant retinitis pigmentosa (adRP) with awaited IND approval from the US FDA
- Ionis’ QR-1123 IV a novel RNA drug- developed by using its own technology indicated in adRP
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
